GAA
PRME icon

Green Alpha Advisors’s Prime Medicine PRME Stock Holding History

Green Alpha Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$665K Buy
191,171
+288
+0.2% +$1.1K 0.66% 45
2025
Q4 		$662K Buy
190,883
+530
+0.3% +$2.36K 0.61% 52
2025
Q3 		$1.05M Buy
190,353
+111,359
+141% +$452K 1.02% 32
2025
Q2 		$195K Sell
78,994
-4,473
-5% -$6.89K 0.19% 94
2025
Q1 		$166K Buy
83,467
+19,061
+30% +$48.6K 0.18% 97
2024
Q4 		$188K Buy
+64,406
New +$226K 0.15% 128
2024
Q3 		– Sell
-26,245
Closed -$135K – 143
2024
Q2 		$135K Sell
26,245
-7,493
-22% -$45.4K 0.11% 127
2024
Q1 		$236K Buy
33,738
+4,200
+14% +$31.9K 0.17% 128
2023
Q4 		$262K Sell
29,538
-8,277
-22% -$63.8K 0.19% 138
2023
Q3 		$361K Buy
37,815
+25,429
+205% +$330K 0.28% 115
2023
Q2 		$181K Buy
+12,386
New +$173K 0.12% 138

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Green Alpha Advisors's PRME Position: Q1 2026 in Review

Green Alpha Advisors increased its Prime Medicine (PRME) stake by 0.15% in Q1 2026, buying an estimated $1.1K and bringing the position to 191,171 shares worth $665K. The position accounts for 0.66% of the portfolio, ranked #45.

Green Alpha Advisors first reported a position in PRME in Q2 2023 and has held it in 11 quarters since. The position peaked at $1.05M in Q3 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Green Alpha Advisors held 191,171 shares of Prime Medicine worth $665K as of Q1 2026.
  • Green Alpha Advisors bought 288 Prime Medicine shares in Q1 2026, an estimated $1.1K.
  • Prime Medicine made up 0.66% of Green Alpha Advisors's portfolio in Q1 2026, its #45 holding.
  • Green Alpha Advisors first reported a position in Prime Medicine in Q2 2023 and has held it in 11 quarters since.
  • Green Alpha Advisors's Prime Medicine position peaked at $1.05M in Q3 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Green Alpha Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.